Boika A.V. , Aleinikava N. Y. , Ponomarev V.V., Ustsiamchuk A.M., Ivanchik H.I.
Parkinsonism syndrome formation in experimental animals. Neuroinflammatory penumbra
Belarusian Medical Academy of Postgraduate Education, Minsk, Republic of Belarus
Vestnik VGMU. 2021;20(4):53-60.
Much valuable information about the development of Parkinson’s disease (PD) has been obtained from studies on the laboratory animals.
Objectives. To compare the development of neurotoxic and neuroinflammatory parkinsonism syndrome in laboratory animals.
Material and methods. The number of rats in the group of neuroinflammatory model of parkinsonism syndrome (lipopolysaccharide) was 6, and in the group of neurotoxic model (rotenone) - 20. The control group consisted of 5 animals. The study was approved by the independent Ethics Committee. The development dynamics of parkinsonism syndrome of neurotoxic and neuroinflammatory genesis was assessed in the study of the motor activity of animals, as well as in the laboratory study of biomarkers of dopamine metabolism (dopamine and homovanillic acid) in blood serum and cerebrospinal fluid obtained in 7 and 21 days after the first administration of rotenone or lipopolysaccharide, and also after a single intravenous injection of allogeneic (rat) multipotent mesenchymal stromal cells (MMSC) carried out after 9 injections of rotenone.
Results. A decrease in the levels of dopamine and homovanillic acid has been shown in laboratory animals on the development of Parkinson’s syndrome. In rats with a neuroinflammatory model of parkinsonism syndrome, a pre-motor stage of motor disorders development has been laboratorially confirmed. During the first weeks after the introduction of MMSC, regression of the motor symptoms of neurotoxic parkinsonism syndrome and a parallel increase in dopamine and homovanillic acid are determined.
Conclusions. The effectiveness of MMSC in the early post-transplantation period is associated with the paracrine effect. It is proposed to call activated microglia, a potential therapeutic target in PD, neuroinflammatory penumbra.
Key words. Parkinson’s disease, neuroinflammatory penumbra, activated microglia, rotenone, lipopolysaccharide, dopamine, homovanillic acid, cell therapy.
Sources of financing
The work was carried out as a part of the Research Project on assignment 19.17 «To develop and implement a method of therapy for Parkinson’s disease using cellular technologies» of the subprogram «Transplantation of cells, organs and tissues» of the State Scientific and Technical Enterprise «New Methods of Medical Aid».
1. Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair. Int J Neurosci. 2015;125(10):717-25. doi: http://dx.doi.org/10.3109/00207454.2014.982795
2. Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Mov Disord. 2021 Jan;36(1):25-36. doi: http://dx.doi.org/10.1002/mds.28411
3. Toovey S, Jick SS, Meier CR. Parkinson's disease or Parkinson symptoms following seasonal influenza. Influenza Other Respir Viruses. 2011 Sep;5(5):328-33. doi: http://dx.doi.org/10.1111/j.1750-2659.2011.00232.x
4. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA. 2009 Aug;106(33):14063-8. doi: http://dx.doi.org/10.1073/pnas.0900096106
5. Jang H, Boltz D, McClaren J, Pani AK, Smeyne M, Korff A, et al. Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci. 2012 Feb;32(5):1545-59. doi: http://dx.doi.org/10.1523/JNEUROSCI.5123-11.2012
6. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al. Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun. 2009 Jan;23(1):55-63. doi: http://dx.doi.org/10.1016/j.bbi.2008.07.003
7. Gundersen V. Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? Front Neurosci. 2021 Feb;14:580311. doi: http://dx.doi.org/10.3389/fnins.2020.580311.e
8. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alphasynuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One. 2010 Jan;5(1):e8784. doi: http://dx.doi.org/10.1371/journal.pone.0008784
9. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005 Apr;19(6):533-42. doi: http://dx.doi.org/10.1096/fj.04-2751com
10. Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. 2008 Oct;22(5):453-64. doi: http://dx.doi.org/10.1111/j.1472-8206.2008.00616.x
11. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA. 2003 Jul;100(14):8514-9. doi: http://dx.doi.org/10.1073/pnas.1432609100
12. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone Model of Parkinson Disease. Multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem. 2005 Dec;280(51):42026-35. doi: http://dx.doi.org/10.1074/jbc.M508628200
13. Aleinikova NE, Boiko AV, Nizhegorodova DB, Ponomarev VV, Vanslav MI, Ustemchuk AM, i dr. Obtaining a toxic chronic model of parkinsonism syndrome in rats. Vestn VGMU. 2018;17(6):92-9. (In Russ.)
14. Boiko AV, Gladkova ZhA, Kuznetcova TE, Ponomarev VV. Simulation of parkinsonism syndrome in rats by administration of lipopolysaccharide. Zhurn Grodn Gos Med Un-ta. 2018;16(6):690-6. (In Russ.)
15. Zafranskaia MM, Nizhegorodova DB, Aleinikova NE, Kuznetcova TE, Vanslav MI, Ignatovich TV, i dr. Migration of multipotent mesenchymal stromal cells during systemic and local administration in an experimental model of parkinsonism. Annaly Klin Eksperim Nevrologii. 2019;13(2):32-40. (In Russ.)
16. Sergeeva TN, Klimova LA, Zakoliukina ES. Morphological changes in the substantia nigra of rats under the influence of lipopolysaccharide of various concentrations. Vestn Udmurt Un-ta. 2017;27(vyp 4):486-91. (In Russ.)
17. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong J-S, et al. Systemic LPS Causes Chronic Neuroinflammation and Progressive Neurodegeneration. Glia. 2007 Apr 1;55(5):453-62. doi: http://dx.doi.org/10.1002/glia.20467
18. Gibbons HM, Dragunow M. Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. Brain Res. 2006 Apr 21;1084(1):1-15. doi: http://dx.doi.org/10.1016/j.brainres.2006.02.032
19. Gao H-M, Jiang J, Wilson B, Zhang W, Hong J-S, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem. 2002 Jun;81(6):1285-97. doi: http://dx.doi.org/10.1046/j.1471-4159.2002.00928.x
20. Ling Z, Zhu Y, wai Tong C, Snyder JA, Lipton JW, Carvey PM. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol. 2006 Jun;199(2):499-512. doi: http://dx.doi.org/10.1016/j.expneurol.2006.01.010
21. Chernivec E, Cooper J, Naylor K. Exploring the Effect of Rotenone-A Known Inducer of Parkinson's Disease-On Mitochondrial Dynamics in Dictyostelium discoideum. Cells. 2018 Nov;7(11):201. doi: http://dx.doi.org/10.3390/cells7110201
22. Skaper SD. Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets. 2011 Feb;10(1):44-56. doi: http://dx.doi.org/10.2174/187152711794488638
23. Khubutiia MSh, Vagabov VA, Temnov AA, Sklifas AN. Paracrine mechanisms of anti-inflammatory and organoprotective action in mesenchymal stem cell transplantation. Literature review. Transplantologiia. 2012;(1-2):20-32. (In Russ.)
24. Gundersen V. Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? Front Neurosci. 2021 Feb;14:580311. doi: http://dx.doi.org/10.3389/fnins.2020.580311
Information about authors:
Boika A.V. – Candidate of Medical Sciences, doctoral candidate of the Chair of Neurology & Neurosurgery, Belarusian Medical Academy of Postgraduate Education;
Aleinikava N.Y. – postgraduate of the Chair of Neurology & Neurosurgery, Belarusian Medical Academy of Postgraduate Education;
Ponomarev V.V. – Doctor of Medical Sciences, professor, head of the Chair of Neurology & Neurosurgery, Belarusian Medical Academy of Postgraduate Education;
Ustsiamchuk A.M. – associate research officer of the Scientific-Research Laboratory, Belarusian Medical Academy of Postgraduate Education;
Ivanchik H.I. – associate research officer of the Scientific-Research Laboratory, Belarusian Medical Academy of Postgraduate Education.